Citations

Bacterial Toxin Research Citations

We’ve gathered published citations for the past many years so that researchers can easily review at their convenience from among the thousands of published articles, how they might use our products in detail or apply these ideas to their own novel thinking for new research.

Search through, read and share our information rich citations below!

Contact us with any questions.

5030 total record number 58 records this year

To narrow your search, use one or more of the following search menus below.

To search by keyword, you may search by the cell/animal/assay/protein/research or publication
Page 1 out of 35
341 citations found

Teixobactin: A Resistance-Evading Antibiotic for Treating Anthrax

Lawrence, WS;Peel, JE;de Winter, R;Ling, LL;Nitti, AG;Peoples, AJ;Shukla, R;MacGillavry, HD;Heine, HS;Hensel, ME;Whorton, EB;Weingarth, M;Lewis, K;Hughes, DE;

Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis

Discovery of Novel Nlrp3 Inhibitors Enabled by a High-Throughput Screen

Dorich, S;Auger, A;Wang, L;Burch, J;Pellerin, C;Chan, S;Raymond, M;Zhang, L;Chefson, A;Germain, M;Jananji, S;Dumais, V;Gaudreault, S;Caron, A;Dumas-Bérube, É;Crackower, M;

Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis

  • NLRC4 Activity in Human Monocytes

    A 10-µL aliquot of compound (10X in 1% DMSO) was added to PMA-differentiated THP1-Null2 cells (65,000 cells in 80 µL of RPMI media per well) and incubated for 60 minutes in a humidified incubator at 37°C with 5% CO2. NLRC4 activation was initiated by adding a 10 µL mixture of LFnNeedle and B. anthracis protective antigen (PA) (List Labs #171E) (10X). LFn-Needle is fused to the amino-terminal domain of LFn (in house). This fusion system, when co-administered with the anthrax toxin’s PA, allows intracellular delivery of the bacterial ligand [11]. OptiMEM (10 µL) was added to control wells in lieu of LFnNeedle/PA treatment. The plate was incubated for 5 hours in a humidified incubator at 37°C with 5% CO2.

    Product #171E – Anthrax Protective Antigen (PA), Recombinant from B. anthracis

DAG-MAG-ΒHB: A Novel Ketone Diester Modulates NLRP3 Inflammasome Activation in Microglial Cells in Response to Beta-Amyloid and Low Glucose AD-like Conditions

Gentili, V;Schiuma, G;Dilliraj, L;Beltrami, S;Rizzo, S;Lara, D;Giovannini, P;Marti, M;Bortolotti, D;Trapella, C;Narducci, M;Rizzo, R;

Product: Anthrax Lethal Factor (LF), Recombinant from B. anthracis

  • 2.13. Priming of Inflammasomes

    Inflammasome activation was measured according to Primiano et al.’s description [28]. HCM3 cells were plated in EMEM without supplements at 1 × 105 cells/well. Cells were stimulated for 1 h with 10 g/mL (13.4 mM) of nigericin (tlrl-nig, InvivoGen, San Diego, CA, USA) for 2 h with 2 mM ATP (tlrl-atpl, InvivoGen), or overnight with 200 g/mL of monosodium urate crystals (MSU; tlrl-msu, InvivoGen) for NLRP3 induction; flagellin/DOTAP complex, obtained with 25 μL HBS buffer with 500 ng flagellin (final concentration at 1 μg/mL; tlrl-stfla, InvivoGen) and 3 μL DOTAP (11202375001, Sigma-Aldrich) for each well for NLRC4 induction; with 0.5 mL Opti-MEM supplemented with GlutaMax (Opti-MEM™ Reduced Serum Medium containing GlutaMAX™ Supplement, 51985034, Gibco, Grand Island, NY, USA) containing 1 μg/mL Bacillus anthracis lethal factor (172B, List Biological Laboratories, Campbell, CA, USA) for 3–6 h for NLRP1 induction; and with a poly(dA:dT)/lipofectamine complex, obtained by mixing 50 μL Opti-MEM containing 1 μg poly(dA:dT) (final concentration at 2 μg/mL) with 50 μL Opti-MEM containing 2.5 μL lipofectamine 2000 (11668027, Thermo Fisher’s Scientific, Waltham, MA, USA) for each well for AIM2 induction. …

    Product #172 – Anthrax Lethal Factor (LF), Recombinant from B. anthracis

Toxin and capsule production by Bacillus cereus biovar anthracis influence pathogenicity in macrophages and animal models

Jiranantasak, T;Bluhm, A;Chabot, D;Friedlander, A;Bowen, R;McMillan, I;Hadfield, T;Hartwig, A;Blackburn, J;Norris, M;

Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis

Vaccinia virus F1Lblocks the ribotoxic stress response to subvert ZAK?-dependent NLRP1 inflammasome activation

Szymanska, I;Bauernfried, S;Komar, T;Hornung, V;

Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis

NLRP1B allele 2 does not respond to Val-boro-Pro (VbP) in the intestinal epithelium

Mazzone, R;Winsor, N;Li, L;Barry, K;Ranger, A;Goyal, S;Meade, J;Bruce, J;Philpott, D;Mogridge, J;Girardin, S;

Product: Anthrax Lethal Factor (LF), Recombinant from B. anthracis

ROS-dependent S-palmitoylation activates cleaved and intact gasdermin D

Du, G;Healy, LB;David, L;Walker, C;El-Baba, TJ;Lutomski, CA;Goh, B;Gu, B;Pi, X;Devant, P;Fontana, P;Dong, Y;Ma, X;Miao, R;Balasubramanian, A;Puthenveetil, R;Banerjee, A;Luo, HR;Kagan, JC;Oh, SF;Robinson, CV;Lieberman, J;Wu, H;

Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis

  • in Columns (ThermoFisher, 88274) according to the 1159 manufacturer’s protocol. 2 ?g/mL endotoxin-removed active and inactive flatox proteins were 1160 mixed with 2 ?g/mL Anthrax Protective Antigen (List Biological Laboratories, 171E) and then were 1161 added to iBMDMs. After 6 hours, cells were treated or n

Immunogenicity and efficacy studies of Endo H in vivo deglycosylated Protective Antigen from Bacillus anthracis as a vaccine candidate against anthrax

Mamedov, T;Gun, N;Gulec, B;Khozeini, H;Ungor, R;Yuksel, D;Arslan, A;Dilik, Z;Deniz, D;Goven, N;Mammadova, G;Hasanova, G;

Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis

  • Immunogenicity Studies of PA83 variants in Mice

    Immunogenicity studies were performed with 3 and 10 μg of plant-produced dPA83(E), dPA83(P) and commercial recombinant PA (rPA, List Biological Laboratories, Campbell, CA, used as a positive control) proteins, administered intraperitoneally in seven- to eight-week-old Balb/c mice (6 animals/group). Mice were injected with three doses of protein samples adsorbed in 0.3% Alhydrogel at three-week intervals (day 0, 21 and 42). …

    Product #171E – Anthrax Protective Antigen (PA), Recombinant from B. anthracis

Species-specific NLRP3 regulation and its role in CNS autoinflammatory diseases

Koller, B;Nguyen, M;Snouwaert, J;Gabel, C;Ting, J;

Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis

  • Anthrax lethal toxin List Biological Laboratories Inc. #171B/#172B

    Treatments

    See Table S1 for list of Figures/panels in each figure and corresponding dose and exposure time. General information for the methods is provided here. To induce cytokine release from macrophages, microglia and BMDM cells were primed for 4–5 h (or time indicated in Table S1)with 1 μg/mL of LPS in culture medium, and some cells were pre-treated with 1 μM of CP456773/MCC950 for 30 min before ATP stimulation. Cells were then pulsed with 5 mM ATP for 30 min. For cytokine induction by anthrax lethal toxin (LeTx), LPS-primed cells were treated with LeTx at a final concentration of 250 ng/mL (LF and PA) for 3 h. Cell supernatants were collected and frozen at −80°C until assayed.

    Product #171E – Anthrax Protective Antigen (PA), Recombinant from B. anthracis
    Prodcut #172 – Anthrax Lethal Factor (LF), Recombinant from B. anthracis

Early Circulating Edema Factor in Inhalational Anthrax Infection: Does It Matter?

Tessier, E;Cheutin, L;Garnier, A;Vigne, C;Tournier, JN;Rougeaux, C;

Product: Anti-Edema Factor from B. anthracis (Goat)

  • goat anti-EF (773L, List Labs, Campbell, CA, USA), …